

Tissue Regenix Group plc
('Tissue Regenix' or the 'Company')

CEO and CFO Share Purchases

Tissue Regenix (AIM: TRX), the regenerative medical device company, announces that on 4 April 2023, Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer each purchased 1,428,570 of the Company's ordinary shares of 0.1p each ("Ordinary Shares").

Name	Title	Number of Ordinary Shares purchased	Resulting beneficial interest in the Company's Ordinary Shares	Percentage of Company's Total Voting Rights
Daniel Lee	Chief Executive Officer	1,428,570	8,690,770	0.12%
David Cocke	Chief Financial Officer	1,428,570	7,120,570	0.10%

For more information:

Tissue Regenix Group plc
David Cocke, Chief Financial Officer

www.tissueregenix.com
Via Walbrook PR

finnCap Ltd (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM

Walbrook PR (Financial PR & IR)
Alice Woodings / Lianne Applegarth

Tel: +44(0)20 7933 8780
TissueRegenix@walbrookpr.com

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in the field of regenerative medicine. The Company's patented decellularisation technology ('dCELL®') removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of high quality, innovative tissue scaffolds, which can enhance healing opportunities in defects created by trauma and disease. CellRight®'s human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Daniel Lee
2	Reason for the notification	
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Tissue Regenix Group plc
b)	LEI	213800PNOD5UHQUFJI36

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1p each GB00B5SGVL29						
b)	Nature of the transaction	Purchase						
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>0.5700p</td><td>500,000</td></tr><tr><td>0.5650p</td><td>928,570</td></tr></table>	Price(s)	Volume(s)	0.5700p	500,000	0.5650p	928,570
Price(s)	Volume(s)							
0.5700p	500,000							
0.5650p	928,570							
d)	Aggregated information - Aggregated volume - Price	1,428,570 £8,096.42						
e)	Date of the transaction	4 April 2023						
f)	Place of the transaction	London Stock Exchange, AIM Market						

1	Details of the person discharging managerial responsibilities / person closely associated								
a)	Name	David Cocke							
2	Reason for the notification								
a)	Position/status	Chief Financial Officer							
b)	Initial notification /Amendment	Initial notification							
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor								
a)	Name	Tissue Regenix Group plc							
b)	LEI	213800PNOD5UHQUFJI36							
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted								
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1p each GB00B5SGVL29							
b)	Nature of the transaction	Purchase							
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>0.5700p</td><td>500,000</td></tr><tr><td>0.5650p</td><td>928,570</td></tr></table>		Price(s)	Volume(s)	0.5700p	500,000	0.5650p	928,570
Price(s)	Volume(s)								
0.5700p	500,000								
0.5650p	928,570								
d)	Aggregated information								

	- Aggregated volume - Price	1,428,570 £8,096.42
e)	Date of the transaction	4 April 2023
f)	Place of the transaction	London Stock Exchange, AIM Market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHKZGGDRDKGFZM